Antibody-based therapy for solid tumors

Cancer Journal

Volumn 14, Issue 3, 2008, Pages 178-183

  Yan, Li ^a   Hsu, Karl ^a   Beckman, Robert A ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

Monoclonal antibodies; Solid tumors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMC 1121B; IMC 18F1; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC 1121B; MONOCLONAL ANTIBODY IMC 18F1; MONOCLONAL ANTIBODY IMC 1C11; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; TUMOR MARKER; VASCULOTROPIN RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BRAIN ISCHEMIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL SURFACE; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INFECTION; LOADING DRUG DOSE; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM; THROMBOSIS; TUMOR CELL; BLOOD; DRUG ANTAGONISM; NEOPLASM; PHARMACOGENETICS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; PHARMACOGENETICS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 52649096967     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318172d71a     Document Type: Review

References (24)

1. Ehrlich P. On immunity with specific reference to cell life. Proc R Soc London. 1900;66:429.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25: 1539-1544.
9. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599 [abstract]. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. 2005;23:4.
10. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23: 792-799.
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
13. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37[suppl 4]:S9-S15.
14. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001;13:506-513.
15. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc). 2003;39[suppl C]:1-16.
16. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
17. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109:170-179.
18. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750-4755.
19. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814s-819s.
20. Chen C, Beckman RA. Optimal cost-effective designs of proof of concept trials and associated Go-No Go decisions. In: American Statistical Association Proceedings of the Biometrics Section, 2007:394-399.
21. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005;11:7872-7878.
22. Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques. 2005;39: 565-568.
23. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-1157.
24. Schaedel O, Reiter Y. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des. 2006;12:363-378.